{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:33:37Z","timestamp":1760297617661},"reference-count":65,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3387,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2006.00957.x","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T11:31:12Z","timestamp":1148470272000},"page":"707-715","source":"Crossref","is-referenced-by-count":42,"title":["Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment"],"prefix":"10.1155","volume":"60","author":[{"given":"H.","family":"Oberwittler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0006-291X(03)00342-5","article-title":"Molecular identification of nicotinic acid receptor","volume":"303","author":"Soga","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0140-6736(04)16359-9","article-title":"The nicotinic acid receptor - a new mechanism for an old drug","volume":"363","author":"Karpe","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB6|cit6","first-page":"271","article-title":"Identification of a nicotinic acid receptor. is that the molecular target for the oldest lipid-lowering drug?","volume":"5","author":"Pike","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bcp.2003.09.014","article-title":"Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin","volume":"67","author":"Rubic","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB8|cit8","unstructured":"Altschul R. Niacin in vascular disorders and hyperlipemia. In Altschul R Charles C Thomas 1964 3 135"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cpt1969104559","article-title":"The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man","volume":"10","author":"Svedmyr","year":"1969","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB10|cit10","first-page":"795","article-title":"Thermographic registration of flush","volume":"21","author":"\u00c5berg","year":"1971","journal-title":"Arzneimittelforschung"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB11|cit11","first-page":"13","article-title":"Inhibition of flush induced by nicotinic acid","volume":"1","author":"\u00c5berg","year":"1973","journal-title":"Int Res Commun"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0773.1977.tb02116.x","article-title":"Studies on the mechanism of flush induced by nicotinic acid","volume":"41","author":"Andersson","year":"1977","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0773.1999.tb01494.x","article-title":"Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man","volume":"84","author":"Saareks","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB16|cit16","first-page":"165","article-title":"The effect of aspirin on niacin-induced cutaneous reactions","volume":"34","author":"Whelan","year":"1992","journal-title":"J Fam Pract"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations for product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB18|cit18","first-page":"773","article-title":"Acute dose-dependent disposition studies of nicotinic acid in rats","volume":"24","author":"Iwaki","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1989.200","article-title":"Pharmacokinetics of nicotinic acid-salicylic acid interaction","volume":"46","author":"Ding","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2006.00957.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"35L","DOI":"10.1016\/S0002-9149(00)01468-5","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol","volume":"86","author":"Piepho","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/ajhp\/60.suppl_2.S9","article-title":"Overview of niacin formulations. differences in pharmacokinetics, efficacy, and safety","volume":"60","author":"Pieper","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1525-1497.1997.07118.x","article-title":"Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions","volume":"12","author":"Jungnickel","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/clpt.1982.63","article-title":"Aspirin blocks nicotinic acid-induced flushing","volume":"31","author":"Wilkin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00045391-199506000-00006","article-title":"Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration","volume":"2","author":"Dunn","year":"1995","journal-title":"Am J Ther"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9149(94)90088-4","article-title":"Fluvastatin with and without niacin for hypercholesterolemia","volume":"74","author":"Jacobson","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/174182679400100308","article-title":"Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients","volume":"1","author":"Tsalamandris","year":"1994","journal-title":"J Cardiovasc Risk"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia","volume":"73","author":"Davignon","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/106002809703100602","article-title":"Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control","volume":"31","author":"Gardner","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/j.1875-9114.1997.tb03095.x","article-title":"Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic","volume":"17","author":"Rindone","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacon (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1067\/mhj.2000.110090","article-title":"Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease","volume":"140","author":"Garg","year":"2000","journal-title":"Am Heart J"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended release niacin vs gemfibrozil for the treatment of low levels of high density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(01)01639-3","article-title":"Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia","volume":"88","author":"McKenney","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1463-1326.2002.00205.x","article-title":"Niacin treatment of the atherogenic lipid profile and Lp (a) in diabetes","volume":"4","author":"Pan","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin","volume":"26","author":"Hunninghake","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0002-9149(03)00394-1","article-title":"Effects of extended-release niacin on lipoprotein subclass distribution","volume":"91","author":"Morgan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis","volume":"164","author":"Insull","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1067\/mhj.2002.120158","article-title":"Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy","volume":"143","author":"Wink","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0002-9149(03)00393-X","article-title":"Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model","volume":"91","author":"Ryan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Dis Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB55|cit55","first-page":"267","article-title":"Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin","volume":"32","author":"Gentile","year":"1985","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2230.1990.tb02071.x","article-title":"Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation","volume":"15","author":"Duteil","year":"1990","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1034\/j.1600-0773.2002.900608.x","article-title":"Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man","volume":"90","author":"Saareks","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the national education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults","volume":"148","author":"Cholesterol Adult Treatment Panel.","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Research Group.","year":"1975","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/archinte.1988.00380110121025","article-title":"Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol\/high-density lipoprotein cholesterol ratio","volume":"148","author":"Luria","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0002-9149(93)90820-3","article-title":"Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans","volume":"71","author":"Schectman","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1994.00420140051007","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archinte.1996.00040041081006","article-title":"Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels","volume":"156","author":"Martin-Jadraque","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1368-5031.2006.00957.x-BIB65|cit65","unstructured":"http:\/\/www.niaspan.com"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2006.00957.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2006.00957.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T14:23:35Z","timestamp":1707056615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2006.00957.x"}},"subtitle":["Asa in The Control of Flushing Related to Na Treatment"],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":65,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2006.00957.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}